HOPKINTON, Mass., Aug. 28 – Alseres
Pharmaceuticals, Inc., (Nasdaq: ALSE), announced that data from preclinical
studies of the Company’s regenerative therapy candidate, ALSE-100, were
presented at the Australian and New Zealand Bone and Mineral Society Annual
Conference, August 28-30, 2008 in Melbourne, Australia.
The poster presentation entitled: “Rho Inhibitor (ALSE-100) effects on
bone cells in vitro” highlighted the results of a study funded by Alseres
and conducted by Dr. Jillian Cornish et al. at the University of Auckland.
The study investigated the effects of ALSE-100 on osteoblast and osteoclast
cells in culture as well as in an organ culture system. ALSE-100 stimulated
differentiation and mineralization to form bone nodules in culture and also
inhibited bone resorption, osteoclast development and activity. These
effects indicate that ALSE-100 could be useful in promoting bone healing.
“Rho inhibitors have previously been shown in published literature to
have a beneficial effect on bone cells,” noted Dr. Noel Cusack, Alseres’
Senior Vice President of Preclinical Development. “We believe that this
study, using a range of doses of one of our Rho inhibitor variants,
ALSE-100, has demonstrated that our Rho inhibitor platform may provide
potentially attractive therapeutic candidates for promoting bone healing.”
About Alseres Pharmaceuticals, Inc.
Alseres Pharmaceuticals, Inc. (ALSE) is engaged in the development of
therapeutic and diagnostic products primarily for disorders in the central
nervous system (CNS). The Company maintains a world-class intellectual
property position in the field of regenerative therapeutics. The Company’s
energy and focus is reflected in several important initiatives. Cethrin, a
recombinant-protein-based drug designed to promote nerve repair after acute
spinal cord injury, demonstrated positive interim results in a Phase I/IIa
clinical trial. The Company’s research and pre-clinical programs include,
Inosine for the treatment of spinal cord injury and stroke, Oncomodulin for
the treatment of ocular injury and disease and research programs directed
at a number of regenerative therapies including bone repair. The Company
has a robust molecular imaging development program targeting diagnosis of
Parkinson’s disease and potentially dementia. The Company’s lead molecular
imaging product candidate is Altropane which is in Phase III clinical
trials for the diagnosis of Parkinsonian Syndromes including Parkinson’s
Disease. The Company has research collaborations with Harvard Medical
School and Children’s Hospital Boston.
Forward-Looking Statements
The foregoing release contains certain forward-looking statements
within the meaning of the Private Securities Litigation Reform Act of 1995.
Forward- looking statements include statements regarding Alseres’ future
expectations, beliefs, intentions, goals, strategies, plans or prospects
regarding the future, including the development and commercialization of
Altropane and Cethrin, the prospects of the Company’s CNS and regenerative
therapeutics programs, the Company’s strategies to develop and
commercialize axon regeneration technologies and the breadth of the
Company’s technologies and intellectual property portfolio. Forward-looking
statements can be identified by terminology such as “anticipate,”
“believe,” “could,” “could increase the likelihood,” “estimate,” “expect,”
“intend,” “is planned,” “may,” “should,” “will,” “will enable,” “would be
expected,” “look forward,” “may provide,” “would” or similar terms,
variations of such terms or the negative of those terms. Such
forward-looking statements involve known and unknown risks, uncertainties
and other factors including those risks, uncertainties and factors referred
to in the Company’s Quarterly Report on Form 10-Q for the quarter ended
June 30, 2008 filed with the Securities and Exchange Commission under the
section “Risk Factors,” as well as other documents that may be filed by
Alseres from time to time with the Securities and Exchange Commission. As a
result of such risks, uncertainties and factors, the Company’s actual
results may differ materially from any future results, performance or
achievements discussed in or implied by the forward-looking statements
contained herein. Alseres is providing the information in this press
release as of this date and assumes no obligations to update the
information in this press release.
Alseres, Cethrin and Altropane are registered trademarks of Alseres
Pharmaceuticals, Inc.
Contact:
Sharon Correia – 508-497-2360 ext. 224
Alseres Pharmaceuticals, Inc.
scorreia@alseres.com
Adam Friedman – 212-981-2529 ext. 18
Adam Friedman Associates
adam@adam-friedman.com
SOURCE Alseres Pharmaceuticals, Inc.